<DOC>
	<DOCNO>NCT02392494</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics MK-1075 , determine ability MK-1075 reduce HCV viral load , follow administration single dose HCV-infected participant .</brief_summary>
	<brief_title>Evaluation MK-1075 Participants With Hepatitis C Virus ( HCV ) Infection ( MK-1075-002 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Male female nonchild bear potential In good health HCV genotype ( GT ) 1 infection Is mentally incapacitate legally institutionalize Has history clinically significant stably control endocrine , gastrointestinal , cardiovascular , hematological , hepatic ( except HCV infection ) , immunological , renal , respiratory , genitourinary major neurological ( include stroke chronic seizure ) abnormality diseases Has history cancer Is positive hepatitis B surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) Has participate another investigational trial within 4 week ( 5 halflives ) prior Screening Consumes &gt; 2 alcoholic beverage day use illegal drug Has evidence history chronic hepatitis cause HCV include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis Has clinical laboratory evidence advance decompensated liver disease , evidence bridge fibrosis high grade fibrosis ( Metavir score â‰¥3 ) prior liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>